Not applicableWithdrawnNCT03872440What this trial is testingPDX Models From EGFR Mutant TumorsWho this might be right forNon Small Cell Lung Cancer Addario Lung Cancer Medical Institute
Early research (Phase 1)Study completedNCT05926180What this trial is testingAssessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)Who this might be right forNon-small Cell Lung Cancer Dizal Pharmaceuticals 25
Large-scale testing (Phase 3)Ended earlyNCT02322281What this trial is testingTIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyWho this might be right forNon-small Cell Lung Cancer Clovis Oncology, Inc. 149
Early research (Phase 1)Looking for participantsNCT05142189What this trial is testingClinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer BioNTech SE 320
Testing effectiveness (Phase 2)Looking for participantsNCT06924398What this trial is testingPostoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）Who this might be right forLung Cancer (NSCLC) Sun Yat-sen University 32
Testing effectiveness (Phase 2)Looking for participantsNCT05284539What this trial is testingEfficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerWho this might be right forNon Small Cell Lung Cancer Hunan Province Tumor Hospital 760
Not applicableUnknownNCT04778800What this trial is testingA Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)Who this might be right forNSCLCBrain MetastasesLeptomeningeal Metastasis Henan Cancer Hospital 60
Testing effectiveness (Phase 2)Study completedNCT03455829What this trial is testingG1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer G1 Therapeutics, Inc. 30
Testing effectiveness (Phase 2)Study completedNCT01573702What this trial is testingStereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)Who this might be right forNon Small Cell Lung Cancer UNC Lineberger Comprehensive Cancer Center 32
Not applicableEnded earlyNCT02431169What this trial is testingGenomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease ProgressionWho this might be right forCarcinoma, Non-Small-Cell-LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer Washington University School of Medicine 5
Testing effectiveness (Phase 2)UnknownNCT00339586What this trial is testingFirst-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR GeneWho this might be right forLung NeoplasmsNon-Small Cell Lung CancerAdenocarcinoma, Bronchiolo-Alveolar Universitair Ziekenhuis Brussel 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05773092What this trial is testingOsimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLCWho this might be right forNSCLC National Cancer Centre, Singapore 30
Not applicableStudy completedNCT03761901What this trial is testingStudy to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in BelgiumWho this might be right forCarcinoma, Non-Small-Cell Lung AstraZeneca 141
Testing effectiveness (Phase 2)UnknownNCT05255406What this trial is testingEfficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)Who this might be right forNon-Small-Cell Lung Cancer Fudan University 62
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06585644What this trial is testingA Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLCWho this might be right forLung Cancer (NSCLC) Shanghai Pulmonary Hospital, Shanghai, China 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT05920135What this trial is testingFirst-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKIWho this might be right forEGFR Mutant Advanced Non-Small Cell Lung Cancer Bridge Biotherapeutics, Inc. 24
Post-approval studies (Phase 4)UnknownNCT05785208What this trial is testingEfficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.Who this might be right forNon Small Cell Lung Cancer Fondazione Policlinico Universitario Agostino Gemelli IRCCS 122
Testing effectiveness (Phase 2)UnknownNCT06334757What this trial is testingSerplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment FailureWho this might be right forNon-Squamous Non-Small Cell Lung Cancer Henan Cancer Hospital 46
Testing effectiveness (Phase 2)Looking for participantsNCT05642572What this trial is testingComparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Who this might be right forRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8 SWOG Cancer Research Network 66
Large-scale testing (Phase 3)UnknownNCT02518802What this trial is testingPemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung AdenocarcinomaWho this might be right forLung Neoplasms Tang-Du Hospital 220